Real-world. Real results.
Discover Bemfola®’s efficacy
and safety.
Discover Bemfola®’s efficacy
and safety.
Number of study sites per region of Spain
BIRTH evaluated four
distinct populations1
distinct populations1
GnRH, gonadotropin-releasing hormone;
OS, ovarian stimulation.
1. Ferrando M, et al. Fertil Res Pract.
2020;6:13.
OS, ovarian stimulation.
1. Ferrando M, et al. Fertil Res Pract.
2020;6:13.
Number of study sites per region of France
REOLA studied the real-world
effectiveness of Bemfola® in
centres throughout France1
effectiveness of Bemfola® in
centres throughout France1
GnRH, gonadotropin-releasing hormone;
OS, ovarian stimulation.
1. Ferrando M, et al. Fertil Res Pract.
2020;6:13.
OS, ovarian stimulation.
1. Ferrando M, et al. Fertil Res Pract.
2020;6:13.
Number of study sites per region of Germany and Austria
German/Austrian NIS: real-
world outcomes with Bemfola®1
world outcomes with Bemfola®1
ART, assisted reproductive technology;
GnRH, gonadotropin-releasing hormone;
NIS, non-interventional study; OS,
ovarian stimulation.
1. Griesinger G, et al. J Reprod Infertil.
2021;22(2):116–124.
GnRH, gonadotropin-releasing hormone;
NIS, non-interventional study; OS,
ovarian stimulation.
1. Griesinger G, et al. J Reprod Infertil.
2021;22(2):116–124.
Click on the map to select a study
The effectiveness and safety of Bemfola® was
demonstrated in three large real-world studies1–3
demonstrated in three large real-world studies1–3
NIS, non-interventional study.
1. Ferrando M, et al. Fertil Res Pract.
2020;6:13; 2. Griesinger G, et al. J
Reprod Infertil. 2021;22(2):116–124; 3.
Barrière P, et al. J Gynecol Obstet Hum
Reprod. 2023;52:10251.
1. Ferrando M, et al. Fertil Res Pract.
2020;6:13; 2. Griesinger G, et al. J
Reprod Infertil. 2021;22(2):116–124; 3.
Barrière P, et al. J Gynecol Obstet Hum
Reprod. 2023;52:10251.
Effective and cost-effective
Bemfola® is cost-effective when compared with alternatives1
Select to find out more
Efficacy
Offering comparable effectiveness at a lower
acquisition price, Bemfola® is a cost-effective
option compared with rFSH alfa originator1,2
acquisition price, Bemfola® is a cost-effective
option compared with rFSH alfa originator1,2
Reduced wastage
Use of single-use pens may lead to reduced
drug wastage compared to use of multi-use
pens2
drug wastage compared to use of multi-use
pens2
Cost savings
Bemfola® may result in lower drug wastage and
better cost-effectiveness compared with
alternative gonadotropins2,3
better cost-effectiveness compared with
alternative gonadotropins2,3
rFSH, recombinant follicle stimulating hormone.
1. Lehmann M, et al. Poster presented at the 39th Annual Meeting of the European
Society of Human Reproduction and Embryology; 25–28 June 2023; Copenhagen,
Denmark; 2. Grynberg M, et al. J Med Econ. 2019;22:108–115. 3. Foxon G, et al.
Hum Fertil (Camb). 2018;21:275–280; 4. Somigliana E, et al. Eur J Obstet Gynecol
Reprod Biol. 2021;267:56–60.
1. Lehmann M, et al. Poster presented at the 39th Annual Meeting of the European
Society of Human Reproduction and Embryology; 25–28 June 2023; Copenhagen,
Denmark; 2. Grynberg M, et al. J Med Econ. 2019;22:108–115. 3. Foxon G, et al.
Hum Fertil (Camb). 2018;21:275–280; 4. Somigliana E, et al. Eur J Obstet Gynecol
Reprod Biol. 2021;267:56–60.
Request details and insights
Your request is received.
Our local team will come back to youshortly with the requested information.
Thank you!